Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke (BCI4STROKE-Arm)
The clinical investigation will take place in three phases:
- A pre-selection/selection phase to ensure that the patient (lesion, symptoms, ability of our tools to detect your movement intentions, etc.) is suitable for a six-month intensive rehabilitation program using Brain-Machine Interface.
- A second phase, consisting of implementing the intensive rehabilitation program, first in the traditional manner, without the Brain-Machine Interface (2 to 5 weeks), then, after implantation, with the Brain-Machine Interface (6 months).
- During the third phase, only follow-up visits will be scheduled to ensure the longevity of the implants and the maintenance of the motor progress achieved through rehabilitation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Caroline SANDRE-BALLESTER, PhD
- Phone Number: 0438782851
- Email: csandreballester@chu-grenoble.fr
Study Contact Backup
- Name: Olivier DETANTE, MD, PhD
- Phone Number: 04 76 76 57 89
- Email: ODetante@chu-grenoble.fr
Study Locations
-
-
-
Grenoble, France, 38000
- Recruiting
- CHUGA
-
Contact:
- Caroline SANDRE-BALLESTER, PhD
- Phone Number: 0438782851
- Email: csandreballester@chu-grenoble.fr
-
Contact:
- Olivier DETANTE, MD, PhD
- Phone Number: 04 76 76 57 89
- Email: ODetante@chu-grenoble.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, 18-70 years-old included
- Hemispheric ischemic stroke (> 1.5 cm on 2 imaging slices): cortical and/or subcortical lesion
- No decompressive craniectomy procedure performed
- Single unilateral stroke occurred 6 months to 18 months ago
- Disabling motor deficit of upper limb
- Patient able to follow a rehabilitation program
- Written consent to participate in the study from the patient and his/her legal representative
- Person affiliated to the social security system or beneficiary of such a system
- Highly effective or at least acceptable birth control method for women of childbearing potential
Exclusion Criteria:
- Contraindication for Magnetic Resonance Imaging (MRI), Computed Tomography (CT-scan), Positron Emission Tomography (PET-scan)
- Contraindication for Transcranial Magnetic Stimulation (TMS), Electroencephalography (EEG), Magnetoencephalography (MEG)
- Contraindication for general anesthesia and for the surgery (such as thrombocytopenia, …)
- Severe leukoaraiosis
- Previous stroke (symptomatic deficit)
- Pre-existing dementia or significant cognitive deficits (MoCA)
- Intolerance to electrical stimulation
- Major spasticity in the upper limb (4 or 5 in the scale of Modified Ashworth Scale - MAS)
- Lesions on the scalp area, skin infections or dermatitis
- Epileptiform focus, even without clinical repercussions
- A health status, any clinical condition (eg, short life expectancy, and coexisting disease) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial
- Presence of brain implants of metal clips and/or brain stimulators
- Severe dystonia/involuntary movements
Patients with any of the following criteria cannot be included in this investigation:
- Contraindication for MRI, CT-scan, PET-scan
- Contraindication for TMS, EEG, MEG
- Contraindication for general anesthesia and for the surgery (such as thrombocytopenia, …)
- Severe leukoaraiosis
- Previous stroke (symptomatic deficit)
- Pre-existing dementia or significant cognitive deficits (MoCA)
- Intolerance to electrical stimulation
- Major spasticity in the upper limb (4 or 5 in the scale of Modified Ashworth Scale - MAS)
- Lesions on the scalp area, skin infections or dermatitis
- Epileptiform focus, even without clinical repercussions
- A health status, any clinical condition (eg, short life expectancy, and coexisting disease) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial
- Presence of brain implants of metal clips and/or brain stimulators
- Severe dystonia/involuntary movements
- Persons referred to in Articles L1121-5 to L1121-7 of the French Public Health Code (CSP), corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, individuals undergoing psychiatric care under Articles L.3212-1 and L.3213-1 who are not covered by Article L.1121-8, individuals admitted to a healthcare or social institution for purposes other than research, and minors.
Moreover, patient will not be included for implantation (exclusion criteria), if he is not eligible for a BCI rehabilitation protocol, as determined by the clinical team after multimodal selection tests. As examples, it can be due to:
- No existing residual corticospinal tracts proven tractography and/or Motor Evoked Potential (MEP)
- Unability to control a BCI or unwillingness to follow a BCI rehabilitation program, assessed by MEG-BCI
- Unability to activate any residual motor regions during motor imagery assessed by EEG and functional MRI (fMRI)
- Shape of the skull in the implantation site not concordant with the WIMAGINE implant, assessed by anatomical MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: REHABCI System
WIMAGINE-based upper-limb neurorehabilitation therapy
|
WIMAGINE
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of a wireless ECoG-based BCI using WIMAGINE® system in stroke patients
Time Frame: 2 years after surgery
|
Serious adverse events associated with the chronic implantation of an extradural ECoG measuring implant
|
2 years after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of the task-oriented rehabilitation program using brain- controlled devices to perform daily life movements
Time Frame: 7 months after surgery
|
Increase in motricity and functional movements of the patient, utilizing assessments such as the Fugl- Meyer Assessment for Upper Extremity (FMA-UE), the Action Research Arm Test (ARAT), the Box and Block Test (BBT) and Range of Motion (RoM)
|
7 months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Benabid AL, Costecalde T, Eliseyev A, Charvet G, Verney A, Karakas S, Foerster M, Lambert A, Moriniere B, Abroug N, Schaeffer MC, Moly A, Sauter-Starace F, Ratel D, Moro C, Torres-Martinez N, Langar L, Oddoux M, Polosan M, Pezzani S, Auboiroux V, Aksenova T, Mestais C, Chabardes S. An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration. Lancet Neurol. 2019 Dec;18(12):1112-1122. doi: 10.1016/S1474-4422(19)30321-7. Epub 2019 Oct 3.
- Mestais CS, Charvet G, Sauter-Starace F, Foerster M, Ratel D, Benabid AL. WIMAGINE: wireless 64-channel ECoG recording implant for long term clinical applications. IEEE Trans Neural Syst Rehabil Eng. 2015 Jan;23(1):10-21. doi: 10.1109/TNSRE.2014.2333541. Epub 2014 Jun 30.
- Eliseyev A, Mestais C, Charvet G, Sauter F, Abroug N, Arizumi N, Cokgungor S, Costecalde T, Foerster M, Korczowski L, Moriniere B, Porcherot J, Pradal J, Ratel D, Tarrin N, Torres-Martinez N, Verney A, Aksenova T, Benabid AL. CLINATEC(R) BCI platform based on the ECoG-recording implant WIMAGINE(R) and the innovative signal-processing: preclinical results. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:1222-5. doi: 10.1109/EMBC.2014.6943817.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025-A01906-43 38RC25.0185
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.